Symbols

TRVI

Trevi Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

Gap Up

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TRVI

Trevi Therapeutics, Inc.

A clinical-stage biopharmaceutical company that develops treatments for prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis

Industry

Pharmaceutical

Established Date

03/17/2011

Listing Date

05/07/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.trevitherapeutics.com

Security Type

Common stock

Office address

195 Church Street, 16th Floor, New Haven, Connecticut 06510

Business

Introduction

Trevi Therapeutics, Inc., was incorporated under the laws of the State of Delaware on March 17, 2011. The Company is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio, an oral sustained-release nalbuphine formulation for the treatment of chronic cough associated with idiopathic pulmonary fibrosis, other interstitial lung diseases and refractory chronic cough. It retains the global commercial rights to the research therapy.

Company Financials

EPS

TRVI has released its 2025 Q4 earnings. EPS was reported at -0.06, versus the expected -0.1, beating expectations. The chart below visualizes how TRVI has performed over recent quarters, highlighting trends in earnings surprises.